SEARCH | CONTACT Our Company Technology Modular Antibody Technology Fcab mAb Our Pipeline Partnering News & Events Careers F-star develops novel bispecific antibodies directed at improving the treatment of serious diseases, with a focus on immuno-oncology and inflammatory diseases. F-star designs and develops bispecific antibody products to improve the treatment of cancer and inflammatory diseases. F-star is the only biopharmaceutical company creating bispecific antibodies by modifying the constant region of an antibody. Our Modular Antibody Technology offers unprecedented ease in the development and manufacturing of genuine bispecific antibody products. MODULAR ANTIBODY TECHNOLOGY Our robust discovery engine lets us easily “mix-and-match” antibody components to create unique bispecific antibody products. PIPELINE F-star develops genuine monoclonal bispecific antibodies that can bind two different targets at the same time, for use as “2-in-1” drugs. NEWS & EVENTS 5 October 2015: FS102 Preclinical Data Publication in Molecular Therapy 9 January 2015: FS102 Enters Phase 1 Clinical Trial 4 November 2014: F-star Creates Second Asset-Centric Vehicle, F-star Beta Ltd OUR COMPANY Company Overview Management Investors Board Scientific Advisors TECHNOLOGY Overview About Bispecifics Modular Antibody Technology™ Fcab™ mAb2™ IP OUR PIPELINE F-star Pipeline F-star Technology Advantage F-star Lead Programme Immuno-Oncology Inflammatory Disease PARTNERING Opportunities Partners NEWS & EVENTS Press Releases F-star in the news Publications Media inquiries Presentations CAREERS © 2015 F-star Biotechnology Limited. All Rights Reserved.